Beyond this, the identification of key target genes (Figure 2), including Argonaute RNA-induced silencing complex (RISC) Catalytic Component 1 (AGO1), Trinucleotide Repeat Containing Adaptor 6B (TNRC6B), NOVA Alternative Splicing Regulator 1 (NOVA1), and Matrix Metallopeptidase 16 (MMP16), offers valuable clues into potential dysregulation in miRNA processing during cancer relapse (52–55). Here, MMP16 is linked to cancer.